Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
The worldwide Dermatomycoses Drug market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 5.3% during the forecast period.
This report presents the market size and development trends by detailing the Dermatomycoses Drug market revenue, market share and growth rate from 2015-2026, and it gives a thorough analysis by various product types, applications, regions, and main participants. The market conditions (2015-2019), corporate competition pattern, corporate SWOT analysis are elaborated, and other qualitative analyses like market dynamics, market penetration, market business environment analyses, the regional regulatory scenario in the Dermatomycoses Drug market will be shown in this report. In short, this report will comprehensively reveal the characteristics of Dermatomycoses Drug industry and will help you to build a panoramic view of the industrial development.
Dermatomycoses Drug Market, By Type:
BB-2603
Clotrimazole
Dapaconazole
Others
Dermatomycoses Drug Market, By Application:
Hospital
Clinic
Others
Some of the leading players are as follows:
Helix BioMedix Inc
Anacor Pharmaceuticals Inc
TGV-Laboratories
Sol-Gel Technologies Ltd
Daewoong Pharmaceutical Co Ltd
Blueberry Therapeutics Ltd
Novan Inc
Vyome Biosciences Pvt Ltd
Dermala Inc
Biolab Farmaceutica Ltda
Viamet Pharmaceuticals Inc
Geographically, Major regions are analyzed in details are as follows:
-
North America
-
Europe
-
Asia Pacific
-
Latin America
-
Middle East & Africa
Table of Contents
1 Methodology and Scope
-
1.1 Market Segmentation & Scope
-
1.1.1 Technology Type
-
1.1.2 Product
-
1.1.3 Application
-
1.1.4 Regional scope
-
1.1.5 Estimates and forecast timeline
-
1.2 Research Methodology
-
1.3 Information Procurement
-
1.3.1 Purchased database
-
1.3.2 Internal database
-
1.3.3 Secondary sources
-
1.3.4 Primary research
-
1.3.5 Details of primary research
-
1.4 Information or Data Analysis
-
1.4.1 Data analysis models
-
1.5 Market Formulation & Validation
-
1.6 Model Details
-
1.6.1 Commodity flow analysis
-
1.6.2 Volume price analysis
-
1.7 List of Secondary Sources
-
1.8 List of Abbreviations
2 Executive Summary
-
2.1 Market Outlook
-
2.2 Segment Outlook
3 Market Variables, Trends, & Scope
-
3.1 Market Lineage Outlook
-
3.1.1 Parent market outlook
-
3.1.2 Ancillary market outlook
-
3.2 Market Segmentation
-
3.2.1 Analysis
-
3.3 Market Dynamics
-
3.3.1 Market driver analysis
-
3.3.2 Market restraint analysis
-
3.3.3 Industry opportunities
-
3.4 Penetration & Growth Prospect Mapping
-
3.4.1 Penetration & growth prospect mapping analysis
-
3.5 Business Environment Analysis Tools
-
3.5.1 Porter's five forces analysis
-
3.5.2 PESTLE analysis
-
3.5.3 Major deals & strategic alliances analysis
4 Dermatomycoses Drug Market: Technology Type Analysis
-
4.1 Dermatomycoses Drug Technology Type Market Share Analysis, 2018 & 2026
-
4.2 Dermatomycoses Drug Technology Type Market: Segment Dashboard
-
4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Technology Type Segment
4.3.1 BB-2603
4.3.2 Clotrimazole
4.3.3 Dapaconazole
4.3.4 Others
5 Dermatomycoses Drug Market: Product Analysis
-
5.1 Dermatomycoses Drug Product Market Share Analysis, 2018 & 2026
-
5.2 Dermatomycoses Drug Product Market: Segment Dashboard
-
5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Product Segment
6 Dermatomycoses Drug Market: Application Analysis
-
6.1 Dermatomycoses Drug Application Market Share Analysis, 2018 & 2026
-
6.2 Dermatomycoses Drug Application Market: Segment Dashboard
-
6.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Application Segment
6.3.1 Hospital
6.3.2 Clinic
6.3.3 Others
7 Dermatomycoses Drug Market: Regional Analysis
-
7.1 Dermatomycoses Drug Regional Market Share Analysis, 2018 & 2026
-
7.2 Dermatomycoses Drug Regional Market: Segment Dashboard
-
7.3 Regional Market Snapshot (Market Size, CAGR, Top Countries)
-
7.4 List of Players at Regional Level
-
7.4.1 North America
-
7.4.2 Europe
-
7.4.3 Asia Pacific
-
7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
-
7.5.1 North America
-
7.5.2 Europe
-
7.5.3 Asia Pacific
-
7.5.4 Latin America
-
7.5.5 MEA
-
7.6 Market Size & Forecasts, and Trend Analysis, 2015 to 2026
-
7.6.1 North America
-
7.6.2 Europe
-
7.6.3 Asia Pacific
-
7.6.4 Latin America
-
7.6.5 Middle East & Africa
8 Competitive Analysis
-
8.1 Recent Developments & Impact Analysis, by Key Market Participants
-
8.2 Strategic Framework/Competition Categorization (Key innovators, Market leaders, Emerging players)
-
8.3 Vendor Landscape
-
8.3.1 Company market position analysis (Geographic presence, service portfolio, strategic initiatives)
9 Company Profiles
9.1 Helix BioMedix Inc
9.1.1 Helix BioMedix Inc Company overview
9.1.2 Financial performance
9.1.3 Product benchmarking
9.1.4 Strategic initiatives
9.1.5 SWOT analysis
9.2 Anacor Pharmaceuticals Inc
9.2.1 Anacor Pharmaceuticals Inc Company overview
9.2.2 Financial performance
9.2.3 Product benchmarking
9.2.4 Strategic initiatives
9.2.5 SWOT analysis
9.3 TGV-Laboratories
9.3.1 TGV-Laboratories Company overview
9.3.2 Financial performance
9.3.3 Product benchmarking
9.3.4 Strategic initiatives
9.3.5 SWOT analysis
9.4 Sol-Gel Technologies Ltd
9.4.1 Sol-Gel Technologies Ltd Company overview
9.4.2 Financial performance
9.4.3 Product benchmarking
9.4.4 Strategic initiatives
9.4.5 SWOT analysis
9.5 Daewoong Pharmaceutical Co Ltd
9.5.1 Daewoong Pharmaceutical Co Ltd Company overview
9.5.2 Financial performance
9.5.3 Product benchmarking
9.5.4 Strategic initiatives
9.5.5 SWOT analysis
9.6 Blueberry Therapeutics Ltd
9.6.1 Blueberry Therapeutics Ltd Company overview
9.6.2 Financial performance
9.6.3 Product benchmarking
9.6.4 Strategic initiatives
9.6.5 SWOT analysis
9.7 Novan Inc
9.7.1 Novan Inc Company overview
9.7.2 Financial performance
9.7.3 Product benchmarking
9.7.4 Strategic initiatives
9.7.5 SWOT analysis
9.8 Vyome Biosciences Pvt Ltd
9.8.1 Vyome Biosciences Pvt Ltd Company overview
9.8.2 Financial performance
9.8.3 Product benchmarking
9.8.4 Strategic initiatives
9.8.5 SWOT analysis
9.9 Dermala Inc
9.9.1 Dermala Inc Company overview
9.9.2 Financial performance
9.9.3 Product benchmarking
9.9.4 Strategic initiatives
9.9.5 SWOT analysis
9.10 Biolab Farmaceutica Ltda
9.10.1 Biolab Farmaceutica Ltda Company overview
9.10.2 Financial performance
9.10.3 Product benchmarking
9.10.4 Strategic initiatives
9.10.5 SWOT analysis
9.11 Viamet Pharmaceuticals Inc
9.11.1 Viamet Pharmaceuticals Inc Company overview
9.11.2 Financial performance
9.11.3 Product benchmarking
9.11.4 Strategic initiatives
9.11.5 SWOT analysis
The List of Tables and Figures (Totals 81 Figures and 128 Tables)
Figure BB-2603 Dermatomycoses Drug market, 2015 - 2026 (USD Million)
Figure Clotrimazole Dermatomycoses Drug market, 2015 - 2026 (USD Million)
Figure Dapaconazole Dermatomycoses Drug market, 2015 - 2026 (USD Million)
Figure Others Dermatomycoses Drug market, 2015 - 2026 (USD Million)
Figure Hospital market, 2015 - 2026 (USD Million)
Figure Clinic market, 2015 - 2026 (USD Million)
Figure Others market, 2015 - 2026 (USD Million)
-
Table List of players in North America
-
Table List of players in Europe
-
Table List of players in Asia Pacific
-
Table SWOT analysis
-
Table North America Dermatomycoses Drug market, by country, 2015 - 2026 (USD Million)
-
Table North America Dermatomycoses Drug market, by type, 2015 - 2026 (USD Million)
-
Table North America Dermatomycoses Drug market, by product, 2015 - 2026 (USD Million)
-
Table North America Dermatomycoses Drug market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table U.S. Dermatomycoses Drug market, by type, 2015 - 2026 (USD Million)
-
Table U.S. Dermatomycoses Drug market, by product, 2015 - 2026 (USD Million)
-
Table U.S. Dermatomycoses Drug market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Canada Dermatomycoses Drug market, by type, 2015 - 2026 (USD Million)
-
Table Canada Dermatomycoses Drug market, by product, 2015 - 2026 (USD Million)
-
Table Canada Dermatomycoses Drug market, by application, 2015 - 2026 (USD Million)
-
Table Europe Dermatomycoses Drug market, by country, 2015 - 2026 (USD Million)
-
Table Europe Dermatomycoses Drug market, by type, 2015 - 2026 (USD Million)
-
Table Europe Dermatomycoses Drug market, by product, 2015 - 2026 (USD Million)
-
Table Europe Dermatomycoses Drug market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table U.K. Dermatomycoses Drug market, by type, 2015 - 2026 (USD Million)
-
Table U.K. Dermatomycoses Drug market, by product, 2015 - 2026 (USD Million)
-
Table U.K. Dermatomycoses Drug market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Germany Dermatomycoses Drug market, by type, 2015 - 2026 (USD Million)
-
Table Germany Dermatomycoses Drug market, by product, 2015 - 2026 (USD Million)
-
Table Germany Dermatomycoses Drug market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table France Dermatomycoses Drug market, by type, 2015 - 2026 (USD Million)
-
Table France Dermatomycoses Drug market, by product, 2015 - 2026 (USD Million)
-
Table France Dermatomycoses Drug market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Italy Dermatomycoses Drug market, by type, 2015 - 2026 (USD Million)
-
Table Italy Dermatomycoses Drug market, by product, 2015 - 2026 (USD Million)
-
Table Italy Dermatomycoses Drug market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Spain Dermatomycoses Drug market, by type, 2015 - 2026 (USD Million)
-
Table Spain Dermatomycoses Drug market, by product, 2015 - 2026 (USD Million)
-
Table Spain Dermatomycoses Drug market, by application, 2015 - 2026 (USD Million)
-
Table Asia Pacific Dermatomycoses Drug market, by country, 2015 - 2026 (USD Million)
-
Table Asia Pacific Dermatomycoses Drug market, by type, 2015 - 2026 (USD Million)
-
Table Asia Pacific Dermatomycoses Drug market, by product, 2015 - 2026 (USD Million)
-
Table Asia Pacific Dermatomycoses Drug market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table China Dermatomycoses Drug market, by type, 2015 - 2026 (USD Million)
-
Table China Dermatomycoses Drug market, by product, 2015 - 2026 (USD Million)
-
Table China Dermatomycoses Drug market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Japan Dermatomycoses Drug market, by type, 2015 - 2026 (USD Million)
-
Table Japan Dermatomycoses Drug market, by product, 2015 - 2026 (USD Million)
-
Table Japan Dermatomycoses Drug market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table India Dermatomycoses Drug market, by type, 2015 - 2026 (USD Million)
-
Table India Dermatomycoses Drug market, by product, 2015 - 2026 (USD Million)
-
Table India Dermatomycoses Drug market, by application, 2015 - 2026 (USD Million)
-
Table Latin America Dermatomycoses Drug market, by country, 2015 - 2026 (USD Million)
-
Table Latin America Dermatomycoses Drug market, by type, 2015 - 2026 (USD Million)
-
Table Latin America Dermatomycoses Drug market, by product, 2015 - 2026 (USD Million)
-
Table Latin America Dermatomycoses Drug market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Brazil Dermatomycoses Drug market, by type, 2015 - 2026 (USD Million)
-
Table Brazil Dermatomycoses Drug market, by product, 2015 - 2026 (USD Million)
-
Table Brazil Dermatomycoses Drug market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Mexico Dermatomycoses Drug market, by type, 2015 - 2026 (USD Million)
-
Table Mexico Dermatomycoses Drug market, by product, 2015 - 2026 (USD Million)
-
Table Mexico Dermatomycoses Drug market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Argentina Dermatomycoses Drug market, by type, 2015 - 2026 (USD Million)
-
Table Argentina Dermatomycoses Drug market, by product, 2015 - 2026 (USD Million)
-
Table Argentina Dermatomycoses Drug market, by application, 2015 - 2026 (USD Million)
-
Table MEA Dermatomycoses Drug market, by country, 2015 - 2026 (USD Million)
-
Table MEA Dermatomycoses Drug market, by type, 2015 - 2026 (USD Million)
-
Table MEA Dermatomycoses Drug market, by product, 2015 - 2026 (USD Million)
-
Table MEA Dermatomycoses Drug market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table South Africa Dermatomycoses Drug market, by type, 2015 - 2026 (USD Million)
-
Table South Africa Dermatomycoses Drug market, by product, 2015 - 2026 (USD Million)
-
Table South Africa Dermatomycoses Drug market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Nigeria Dermatomycoses Drug market, by type, 2015 - 2026 (USD Million)
-
Table Nigeria Dermatomycoses Drug market, by product, 2015 - 2026 (USD Million)
-
Table Nigeria Dermatomycoses Drug market, by application, 2015 - 2026 (USD Million)
-
Table Recent Developments & Impact Analysis, by Key Market Participants
-
Table Recent Developments & Impact Analysis, by Key Market Participants
-
Table Company market position analysis
Table Company Profiles
Table Helix BioMedix Inc Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Anacor Pharmaceuticals Inc Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table TGV-Laboratories Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Sol-Gel Technologies Ltd Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Daewoong Pharmaceutical Co Ltd Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Blueberry Therapeutics Ltd Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Novan Inc Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Vyome Biosciences Pvt Ltd Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Dermala Inc Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Biolab Farmaceutica Ltda Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Viamet Pharmaceuticals Inc Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
-
